Dublin, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Acute Coronary Syndrome: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering. The $1.9bn acute coronary syndrome (ACS) market will experience moderate growth over the forecast period, driven by uptake of Brilinta and Xarelto in the secondary-prevention setting. This report addresses the following questions: - How will the updated 2016 treatment guidelines impact the use of new antiplatelet agents Effient and Brilinta? - How will Brilinta's label expansion impact its sales within ACS? - How will Xarelto's expected US approval in ACS affect its patient share in comparison to generic warfarin? - What are the most commonly prescribed therapies for ACS in the acute and secondary-prevention treatment settings? - What are the most important factors influencing prescribing trends in ACS? Key Topics Covered: FORECAST: ACUTE CORONARY SYNDROME - Executive Summary - Market Overview and Trends - Market Definition and Methodology - Angiomax (bivalirudin) - Brilinta (ticagrelor) - Effient (prasugrel) - Kengreal (cangrelor) - Plavix (clopidogrel) - Xarelto (rivaroxaban) - Zontivity (vorapaxar) - Primary Research Methodology TREATMENT: ACUTE CORONARY SYNDROME - Executive Summary - Primary Research Methodology - Disease Definition and Diagnosis - Patient Segmentation - Country Treatment Trees - Prescribing Trends EPIDEMIOLOGY: ACUTE CORONARY SYNDROME IN THE US, JAPAN, AND 5EU - Executive Summary - Disease Definition - Global Variation - Risk Factors - Co-Morbidities - Sources and Methodology - Forecast - Epidemiologist Insight - Strengths and Limitations - Bibliography MARKETED DRUGS: ACUTE CORONARY SYNDROME - Executive Summary - Product Overview - Product profile: Angiomax - Product profile: Brilinta - Product profile: Effient - Product profile: Kengreal - Product profile: Plavix - Product profile: Xarelto - Product profile: Zontivity For more information about this report visit http://www.researchandmarkets.com/research/tq...e_coronary Related Topics: Cardiovascular Drugs
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716